EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab

Hiroyuki Suzuki iD, Tomokazu Ohishi iD, Tomohiro Tanaka, Mika K Kaneko iD, Yukinari Kato iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Hiroyuki Suzuki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Antibody-Dependent Cell Cytotoxicity, Cricetulus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-specific monoclonal antibodies (CasMabs) that recognize cancer-specific antigens with in vivo antitumor efficacy are innovative therapeutic strategies for minimizing adverse effects. We previously established a cancer-specific anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody (mAb), H2Mab-250/H2CasMab-2. In flow cytometry and immunohistochemistry, H2Mab-250 reacted with HER2-positive breast cancer cells but did not show reactivity to normal epithelial cells. In contrast, a clinically approved anti-HER2 mAb, trastuzumab, strongly recognizes both breast cancer and normal epithelial cells in flow cytometry. The human IgG1 version of H2Mab-250 (H2Mab-250-hG1) possesses compatible in vivo antitumor effects against breast cancer xenografts to trastuzumab despite the lower affinity and effector activation than trastuzumab in vitro. This study compared the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDC) between H2Mab-250-hG1 and trastuzumab. Both H2Mab-250-hG1 and trastuzumab showed ADCC activity against HER2-overexpressed Chinese hamster ovary -K1 and breast cancer cell lines (BT-474 and SK-BR-3) in the presence of human natural killer cells. Some tendency was observed where trastuzumab showed a more significant ADCC effect compared to H2Mab-250-hG1. Importantly, H2Mab-250-hG1 exhibited superior CDC activity in these cells compared to trastuzumab. Similar results were obtained in the mouse IgG2a types of both H2Mab-250 and trastuzumab. These results suggest the different contributions of ADCC and CDC activities to the antitumor effects of H2Mab-250-hG1 and trastuzumab, and indicate a future direction for the clinical development of H2Mab-250-hG1 against HER2-positive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntibody-Dependent Cell CytotoxicityCricetulusAnimalsHumansCHO CellsCell Line, TumorFemaleBreast NeoplasmsAntineoplastic Agents, ImmunologicalAntibodies, MonoclonalComplement System ProteinsMiceCricetinae

Stichwörter der Autor:innen

HER2antitumor effectcancer-specific monoclonal antibodycomplement-dependent cellular cytotoxicity

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalAntibodies, MonoclonalComplement System ProteinsERBB2 protein, human

Autor:innen und Institutionen

  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
  • Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
  • Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.

ORCID-Profile: Hiroyuki Suzuki, Tomokazu Ohishi, Mika K Kaneko, Yukinari Kato

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., & Kato, Y. (2024). Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158386

Vancouver

Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y. Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158386

BibTeX
@article{Suzuki2024,
  author = {Suzuki, Hiroyuki and Ohishi, Tomokazu and Tanaka, Tomohiro and Kaneko, Mika K and Kato, Yukinari},
  title = {Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158386}
}
Kostenlos starten →